Cited 11 times in
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2020-07-27T16:40:55Z | - |
dc.date.available | 2020-07-27T16:40:55Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/178449 | - |
dc.description.abstract | Purpose: This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients. Methods: Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m(2) on day 1, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints. Results: Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95% CI 2.580-16.064)] was independently associated with OS. Age (≥60 years) and serum AFP level (≥200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95% CI 1.543-15.850), P = 0.048, HR 2.677 (95% CI 1.010-7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups. Conclusions: Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Verlag | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / pathology | - |
dc.subject.MESH | Cisplatin / administration & dosage | - |
dc.subject.MESH | Cisplatin / adverse effects | - |
dc.subject.MESH | Cisplatin / therapeutic use | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Doxorubicin / administration & dosage | - |
dc.subject.MESH | Doxorubicin / adverse effects | - |
dc.subject.MESH | Doxorubicin / therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil / administration & dosage | - |
dc.subject.MESH | Fluorouracil / adverse effects | - |
dc.subject.MESH | Fluorouracil / therapeutic use | - |
dc.subject.MESH | Hepatic Artery | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intra-Arterial | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms / drug therapy* | - |
dc.subject.MESH | Liver Neoplasms / pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Myeong Jun Song | - |
dc.contributor.googleauthor | Si Hyun Bae | - |
dc.contributor.googleauthor | Ho Jong Chun | - |
dc.contributor.googleauthor | Jong Young Choi | - |
dc.contributor.googleauthor | Seung Kew Yoon | - |
dc.contributor.googleauthor | Jun Young Park | - |
dc.contributor.googleauthor | Kwang Hyub Han | - |
dc.contributor.googleauthor | Young Seok Kim | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Woo Jin Chung | - |
dc.contributor.googleauthor | Jae Seok Hwang | - |
dc.contributor.googleauthor | Sung-Bum Cho | - |
dc.contributor.googleauthor | Jong Ryul Eun | - |
dc.identifier.doi | 10.1007/s00280-015-2692-0 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 25663125 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00280-015-2692-0 | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 75 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 739 | - |
dc.citation.endPage | 746 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.75(4) : 739-746, 2015-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.